Preparing for Expanded Clinical Trial Data Transparency US and EU Initiatives on the Horizon

Quantity Discounts
1 - 9999
1 - 9999
1 - 9999
1 - 9999
1 - 9999
1 - 9999
1 - 9999
1 - 9999
In just the last three months, a slew of different initiatives for expanded clinical trial data disclosure and transparency has been introduced in the US and EU. Big changes are on the horizon that could significantly disrupt sponsors’ disclosure policies and operational procedures.

In the US:

  • The Trial and Experimental Studies Act is aimed to close disclosure loopholes and make sure end results are posted.
  • The Clinical Trial Cancer Mission 2020 Act wants companies to disclose results, good and bad.
  • Under FDASIA Section 1124, the FDA is proposing to make available de-identified and masked data from medical product applications. Industry claims this is illegal.

In Europe, the EU’s parliament announced in June it intends to release clinical trial data on all newly-approved drugs to promote faster innovation and establish “trust and confidence in the system.”

Your clinical trial data could be a much more open book.  Are you prepared?

Register Today

Full disclosure of clinical trial results is one of this year’s hot issues for pharmaceutical and medical device companies and U.S. and EU regulatory bodies are clear that changes are coming.

If you aren’t keeping tabs on all of what is on the horizon, you might be blindsided about what information you have to hand over.

FDAnews, along with one of the leading experts in clinical trial disclosure, Scott Cunningham, will provide a roadmap detailing how the latest initiatives could radically impact your company’s trial design, data collection and reporting strategies.

Register now.

  • Medical Affairs Officers
  • Director of Clinical Operations
  • Regulatory Affairs Professionals
  • Director of Publications
  • Director of Clinical Trial Regulatory Management
  • Clinical Trial Information Disclosure Directors
  • Global Clinical Safety and Pharmacovigilance Officers

Scott Cunningham, Esq is a partner at Covington & Burling LLP, where he is a member of the FDA practice group and both a frequent speaker and writer. Mr. Cunningham has significant experience in areas including new product development and clinical trials; IRBs; new product approvals; Hatch-Waxman exclusivities and product life-cycle management; advertising and promotion; False Claims Act and Anti-Kickback compliance issues and pharmaceutical investigations; Orphan Drug; pediatric exclusivity; manufacturing and cGMPs; import/export; controlled substances; SEC disclosure; and other aspects of federal and state regulation of pharmaceuticals, biologics, and medical devices.

Register now!

Date: Monday, Sept. 30, 2013
Location: Your office or conference room (no need to travel!)
Time: 1:30 p.m. – 3:00 p.m. EDT
  12:30 p.m. – 2:00 p.m. CDT
  11:30 a.m. – 1:00 p.m. MDT
  10:30 a.m. – 12:00 p.m. PDT
  6:30 p.m. – 8:00 p.m. BST

Gather your team for maximum benefit! Your investment is for one dial-in.

Interested in registering multiple sites?

Significant tuition discounts are available for three or more sites from
the same company. You must register at the same time and
provide a single payment to take advantage of the discount. Register below
by clicking on add to cart and then change your quantity in the shopping cart.
The discount will be calculated automatically.

3-4 sites – 10%
7-9 sites – 20%
5-6 sites – 15%
10+ sites – 25%

Call (888) 838-5578 in the U.S. or +1 (703) 538-7600 globally
with any questions.

Check your local time against the times above. (Washington, D.C. is representative of Eastern time.)

Can't make the scheduled date and time? See the 24/7 ENCORE option described below.

Five Cost-Effective Tuition Options
All participants of the live session are eligible to receive a certificate of attendance.

Payment is required by the date of the webinar. We accept American Express, Visa and MasterCard. Make checks payable to FDAnews.

Or, register by phone: toll free (888) 838-5578 (inside the U.S.) or +1 (703) 538-7600

Webinar registrations may not be cancelled. Registrants may substitute the 24/7 ENCORE™ audio presentation or the CD/transcript package for the live webinar at any time. Please contact customer service to make any substitutions. No shows will automatically be shipped the CD/transcript package, including the speaker's presentation. (Additional shipping and handling charges for the CD/transcript package may apply.)

Interested in Becoming a Speaker?
We're always looking for industry leaders eager to share their expertise at an FDAnews audioconference, webinar or physical conference. Our seasoned speaker community includes executives in the pharmaceutical, medical device and clinical trial industries, regulatory affairs, quality control, compliance, healthcare and academia, as well as several former — and current — top FDA officials. Click here to complete our speaker opportunity form and have a representative contact you about future opportunities.